AZN

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.81
Percentage change -1.14	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM DFIC FVD DIHP TQQQ PVAL AVDE PPH QYLD

Scroll to Statements

Index	NDX	P/E	28.10	EPS (ttm)	2.49	Insider Own	0.01%	Shs Outstand	3.10B	Perf Week	-6.73%
Market Cap	216.94B	Forward P/E	13.72	EPS next Y	5.10	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	0.04%
Enterprise Value	243.28B	PEG	2.48	EPS next Q	1.10	Inst Own	16.55%	Short Float	0.22%	Perf Quarter	-8.59%
Income	7.77B	P/S	3.95	EPS this Y	10.35%	Inst Trans	0.87%	Short Ratio	1.30	Perf Half Y	5.62%
Sales	54.98B	P/B	5.29	EPS next Y	12.57%	ROA	7.45%	Short Interest	6.92M	Perf YTD	6.76%
Book/sh	13.23	P/C	40.21	EPS next 5Y	11.35%	ROE	19.81%	52W Range	61.24 - 87.68	Perf Year	-11.80%
Cash/sh	1.74	P/FCF	18.92	EPS past 3/5Y	285.87% 34.63%	ROIC	11.28%	52W High	-20.22%	Perf 3Y	18.04%
Dividend Est.	1.61 (2.31%)	EV/EBITDA	13.47	Sales past 3/5Y	12.64% 17.27%	Gross Margin	72.58%	52W Low	14.22%	Perf 5Y	32.88%
Dividend TTM	1.55 (2.22%)	EV/Sales	4.42	EPS Y/Y TTM	22.70%	Oper. Margin	20.63%	Volatility	1.41% 1.37%	Perf 10Y	112.97%
Dividend Ex-Date	Feb 21, 2025	Quick Ratio	0.70	Sales Y/Y TTM	15.48%	Profit Margin	14.14%	RSI (14)	42.41	Recom	1.37
Dividend Gr. 3/5Y	2.54% 2.10%	Current Ratio	0.90	EPS Q/Q	33.73%	SMA20	-3.02%	Beta	0.39	Target Price	92.41
Payout	66.98%	Debt/Eq	0.77	Sales Q/Q	7.17%	SMA50	-0.24%	Rel Volume	1.17	Prev Close	70.76
Employees	94300	LT Debt/Eq	0.68	Earnings	Apr 29 BMO	SMA200	-2.44%	Avg Volume	5.34M	Price	69.95
IPO	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.52% -1.60%	Trades		Volume	6,262,727	Change	-1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Jun-20-25 09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-19-25 09:47AM	Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? (Zacks)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
Jun-17-25 05:16PM	Trump's big beautiful bill: What the pharma industry is watching (Yahoo Finance Video)
02:39PM	Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards? (Zacks)
06:15PM	Loading…
Jun-16-25 06:15PM	Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
08:29AM	EHA 2025: AstraZenecas surovatamig is potential next-gen BiTE for R/R B-ALL (Pharmaceutical Technology)
Jun-15-25 05:39AM	AstraZeneca's ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer (Insider Monkey)
Jun-13-25 12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
12:19PM	AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal (Pharmaceutical Technology)
12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:29AM	AstraZeneca Enters Deal With CSPC Pharma Valued at Up to $5.33 Billion (The Wall Street Journal)
05:11AM	The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies (Zacks)
04:40AM	AstraZeneca signs AI research deal with China's CSPC for chronic diseases (Reuters)
04:43PM	Loading…
Jun-12-25 04:43PM	Top Stock Reports for Microsoft, AstraZeneca & BlackRock (Zacks)
10:21AM	PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds (Zacks)
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
Jun-10-25 06:15PM	Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know (Zacks)
03:00PM	Is IonQ a Better Quantum Computing Stock to Buy Than D-Wave? (Zacks)
10:50AM	Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants (Zacks)
10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks)
10:10AM	RFK Jr. removes CDC vaccine panel members: What to know (Yahoo Finance Video)
Jun-09-25 03:00PM	Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? (Zacks)
12:39PM	AstraZeneca and Pangaea partner for AI detection of hypophosphatasia (Medical Device Network)
11:33AM	IonQ Stock Unveils UK Oxford Ionics Acquisition, Nvidia Quantum Collaboration (Investopedia)
11:08AM	Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. (Barrons.com)
11:00AM	Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season (Benzinga)
07:23AM	IonQ To Buy Oxford Ionics In $1 Billion Deal As Acquisition Spree Continues (Investor's Business Daily)
04:57AM	EC approves AstraZenecas acalabrutinib combo for CLL (Pharmaceutical Technology)
11:31AM	Loading…
Jun-06-25 11:31AM	Why Is Techne (TECH) Down 3% Since Last Earnings Report? (Zacks)
09:45AM	Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term (Zacks)
09:12AM	Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? (Zacks)
Jun-05-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
02:00AM	Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains. (Barrons.com)
Jun-04-25 12:03PM	Daiichi Sankyo struck gold with ADC cancer drugs. Its new CEO has to figure out whats next. (BioPharma Dive)
Jun-02-25 06:15PM	Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
01:15PM	AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO (Benzinga)
12:53PM	ASCO25: AstraZenecas novel trial design for camizestrant pays off in breast cancer (Clinical Trials Arena)
11:23AM	AstraZeneca CEO Pascal Soriot on breast cancer drug trial (CNBC TV)
09:23AM	AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment (CNBC TV)
08:00AM	How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma (Investor's Business Daily)
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial (Business Wire)
07:22AM	Experimental AstraZeneca pill helps cut risk of breast cancer progression (CNBC TV)
04:00AM	Enhertu potential broadens as new data point to frontline breast cancer role (BioPharma Dive)
Jun-01-25 08:05AM	IMFINZI (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial (Business Wire)
08:03AM	Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk (Reuters)
08:00AM	Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial (Business Wire)
07:10AM	A funding flashpoint, Pfizers $1B poster and AstraZeneca advertising (BioPharma Dive)
04:00AM	AstraZeneca drug could help keep a common breast cancer at bay (BioPharma Dive)
May-31-25 04:00AM	At ASCO, Enhertu cements growing role in stomach cancer care (BioPharma Dive)
May-30-25 09:22PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
11:50AM	Danaher Partners With AstraZeneca to Support Precision Medicine (Zacks)
11:31AM	Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue? (Zacks)
10:12AM	Danaher and AstraZeneca to develop diagnostic tools and tests (Medical Device Network)
May-29-25 11:11PM	Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests (Insider Monkey)
04:30PM	Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine (PR Newswire)
May-28-25 09:22AM	Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
09:45AM	Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders (PR Newswire)
May-26-25 03:00PM	Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy? (Zacks)
09:38AM	Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer (Zacks)
May-23-25 05:37AM	Aptar Digital to use AstraZenecas AI algorithms for CKD detection (Pharmaceutical Technology)
May-21-25 11:10AM	FDA to mandate trials for COVID boosters for healthy kids and adults (TipRanks)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:13AM	The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust (Zacks)
09:05AM	AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip? (Zacks)
07:00AM	AstraZenecas record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer (Business Wire)
May-20-25 09:41PM	3 Promising Growth Stocks You Can Buy for Less Than $100 (Motley Fool)
04:54PM	Top Research Reports for Visa, AstraZeneca & Shell (Zacks)
12:20PM	AstraZeneca says Airsupra reduced severe asthma risk by 47% (TipRanks)
10:22AM	MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug (Zacks)
08:58AM	Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study (Zacks)
08:00AM	How Does D-Wave Stack Up Against Quantum Competitors? (MarketBeat)
07:33AM	From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room (PR Newswire)
May-19-25 08:06PM	AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% (Insider Monkey)
12:34PM	Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma (Business Wire)
May-17-25 09:30AM	Trump administration not backing down on Big Pharma pressure campaign (Yahoo Finance)
May-15-25 03:00PM	After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-13-25 04:59PM	Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? (Insider Monkey)
09:56AM	Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:00AM	AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 (Business Wire)
05:10AM	MHRA approves AstraZenecas Trixeo Aerosphere inhaler for COPD (Pharmaceutical Technology)
May-12-25 04:54PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
07:38AM	Trumps Vow to Cut US Drug Prices Drags Pharma Stocks Lower (Bloomberg)
07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
07:15AM	AstraZenecas Imfinzi combo shows DFS improvement in bladder cancer trial (Clinical Trials Arena)
04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
May-09-25 09:55AM	How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89% (Zacks)
08:51AM	Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update (Zacks)
07:00AM	IMFINZI (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial (Business Wire)
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks)
07:45AM	Tempus AI Stock: Time to Double Down or Cut and Run? (MarketBeat)
05:37AM	AstraZeneca, Daiichis Enhertu shows pCR rate improvement in breast cancer trial (Clinical Trials Arena)
05:37AM	AstraZeneca and Daiichis Enhertu shows pCR rate improvement in breast cancer trial (Clinical Trials Arena)
May-07-25 11:18PM	Hartford International Equity Fund Q1 2025 Commentary (Seeking Alpha)
05:46PM	Hartford International Opportunities Fund Q1 2025 Commentary (Seeking Alpha)
02:54PM	AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer (Seeking Alpha)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience